Liane M. Peterson is a first chair trial litigator with extensive experience handling IP litigation matters in U.S. district courts and before the U.S. International Trade Commission (ITC). She is co-chair of the firm’s IP Litigation Practice and a member of the Chemical, Biotechnology & Pharmaceutical Practice. Liane is also a member of the Life Sciences Industry Team as well as the Health Care & Life Sciences and Innovative Technology Sectors.
Liane focuses her practice on complex patent litigation in the pharmaceutical and biotechnology fields, with a particular focus on Hatch-Waxman litigation. She has represented numerous pharmaceutical, biologics, and life sciences companies in litigation at the district court and appellate levels across a wide range of matters involving small molecule drugs, biologics, medical devices, cosmetics, vaccines, and diagnostics. Liane also routinely counsels clients, including startups, and both large pharmaceutical companies and those engaged in early-stage clinical research on a range of pre-litigation matters.
Liane also has significant experience handling Section 337 patent litigation for clients at the ITC and routinely assists clients with a range of IP disputes, including licensing matters, trade secret misappropriation, unfair competition and antitrust claims.
Liane previously worked as a law clerk at the ITC in the Office of Unfair Import Investigations dealing with Section 337 investigations of unfair trade practices involving intellectual property rights. Prior to law school she served as a researcher at The Institute for Genomic Research in Rockville, Md.
대표 경험
Pharmaceutical and Life Sciences Cases
- Allustra Technologies LLC v. Clarins USA, Inc., 1:22-cv-09948 (S.D.N.Y.)
- Trutek Corp. v. BlueWillow Biologics, Inc., 4:21-cv-10312 (E.D. Mich.)
- Ravgen, Inc. v. Myriad Genetics, Inc., 1:20-cv-01730 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Natco Pharma Ltd., 1:19-cv-02368 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. MSN Laboratories Private Ltd., 1:19-cv-02342 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Accord Healthcare Inc., 1:19-cv-02321 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialties Ltd., 1:19-cv-02309 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., 1:18-cv-00758 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, 1:18-cv-00699 (D. Del.)
- NuGEN Technologies, Inc. v. Keygene NV, 4:18-cv-00525 (N.D. Cal.)
- Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC, 1:17-cv-01429 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc., et al., 1:15-cv-00328 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., 1:15-cv-00249 (D. Del.)
- Unimed Pharmaceuticals LLC, et al. v. Sandoz, Inc., 1:15-cv-01120 (D. Del.)
- Unimed Pharmaceuticals LLC, et al. v. Lupin Atlantis Holdings SA, 1:15-cv-00904 (D. Del.)
- AstraZeneca LP, et al. v. HEC Pharm Co., Ltd., 1:15-cv-01041 (D. Del.)
- Actavis Laboratories UT, Inc. v. Par Pharmaceutical, Inc., 1:15-cv-00886 (D. Del.)
- Sebela Pharmaceuticals v. Prinston Pharmaceutical, 2:14-cv-07400 (D.N.J.)
- Sebela Pharmaceuticals v. Actavis Laboratories FL, Inc., 2:14-cv-06414 (D.N.J.)
- Par Pharmaceutical, Inc. v. GlaxoSmithKline LLC and Aptalis Pharma, 1:14-cv-06627 (E.D. Pa.)
- AstraZeneca v. Sagent Pharmaceuticals, Inc. and Glenmark Pharmaceuticals Ltd., 1:14-cv-03547 (D.N.J.)
- Lyne Laboratories, Inc., et al. v. Lupin Ltd., 1:14-cv-10153 (D. Mass.)
- Unimed Pharmaceuticals LLC, et al. v. Perrigo Co., et al., 1:13-cv-00236 (D. Del.)
- Boehringer Ingelheim et al. v. Kremers Urban Pharmaceuticals Inc., 1:13-cv-01580 (D.N.J.)
- Keygene NV v. Floragenex Inc., 3:11-cv-00803 (D. Or.)
- Pfizer Inc. et al. v. Kremers Urban, LLC, et al. (D. Del.)
- Sepracor Inc. et al. v. Pharmaceutical Associates, Inc. (D.N.J.)
- Schering Corp. v. Geopharma, Inc. (D.N.J.)
- Sanofi-Aventis v. Ebewe Pharma (D.N.J.)
ITC Cases
- Certain Residential Premises Security Monitoring and Automation Control Panels, 337-TA-1273
- Certain Fitness Devices, 337-TA-1265
- Certain Wearable Monitoring Devices, 337-TA-1190
- Certain Semiconductor Devices, Semiconductor Device Packages, and Products Containing Same, 337-TA-1010
- Certain Computing or Graphics Systems, Components Thereof, and Vehicles Containing Same, Inv. No. 337-TA-984
- Certain Dental Implants, Inv. No. 337-TA-934
- Certain Integrated Circuits and Products Containing Same, Inv. No. 337-TA-920
- Certain Optoelectronic Devices for Fiber Optic Communications, Inv. No. 337-TA-860
- Certain Motion Sensitive Sound Effects Devices and Image Display Devices and Components and Products Containing Same, Inv. No. 337-TA-773
- Certain Buffer Systems and Components Thereof Used in Container Processing Lines, Inv. No. 337- TA-609
- Certain Lighting Control Devices Including Dimmer Switches and/or Switches and Parts Thereof, Inv. No. 337-TA-599
- Certain Shirts with Pucker-Free Seams and Methods of Producing Same, Inv. No. 337-TA-517
수상 및 표창
- IAM Patent 1000 – The World’s Leading Patent Practitioners (2025)
제휴
- 미국 변호사 협회 회원
- Member, American Intellectual Property Association
- Member, International Trade Commission Trial Lawyers Association
- 연방 순회 변호사 협회 회원
프레젠테이션 및 출판물
- “GLP-1 Receptor Agonists: Drug Litigation Overview and Trends,” Health Care Law Today (April 2, 2025)
- “Top Trends to Watch in Pharmaceutical Litigation,” Foley Health Care & Life Sciences Webinar (October 12, 2023)
- “U.S. Patent Litigation, including ITC, Hatch-Waxman and Biosimilar Litigation Proceedings,” presented with Lee & Ko and Korea Pharmaceutical and Bio-Pharma Manufacturers Association (September 26, 2023)
- “Statistics, Trends and Developments in Popular U.S. Patent Litigation Jurisdictions,” Japan Intellectual Property Association (September 27, 2023)
- “Timing Considerations for Section 337 Investigations and IPRs,” Bloomberg Law Professional Perspectives (October 13, 2022)
- “Hot Topics in U.S. Patent Litigation,” Winning in the Unknown – U.S. Intellectual Property Development Seminar Series (January 27, 2021)
- “Assessing the Limitations and Prospects of Obviousness-Type Double Patenting,” ACI Paragraph IV Disputes, New York (August 20-21, 2020)
- “Hatch-Waxman and BPCIA Fundamentals: Examining Follow-On Products and the Rules for Generic Entry,” ACI FDA Boot Camp, New York (March 23-25, 2020) (invited to speak; program cancelled)
- “Hot Topics on Patent Litigation,” 2019 Tokyo IP Conference (October 16, 2019)
- “Assessing Secondary Considerations in Light of Blocking Patents Post-Acorda,” ACI Paragraph IV Disputes, New York (April 29-30, 2019)
- “Latest Patent Litigation and IPR Considerations for Japanese Companies” and “USITC As Successful Venue for Patent Owners,” 2018 Tokyo IP Conference (October 11, 2018)
- “Deciphering the Business Implications of the On-Sale Bar,” ACI Paragraph IV Disputes, New York (April 23-24, 2018)
- “Hatch-Waxman Year-in-Review Panel,” ABA IP Law Section Annual Conference (April 7, 2016)
- “e-Discovery in U.S. Patent Litigation,” Advanced U.S. Patent Litigation Seminar Series, Osaka, Japan and Tokyo, Japan (January 27-28, 2016)
- “Beginning the Litigation: Initial Considerations and Strategies,” U.S. Patent Litigation Seminar Series, Osaka, Japan (May 15, 2014)
- Hatch-Waxman Litigation Seminar, Japan Pharmaceutical Manufacturers Association IP Committee, Tokyo, Japan (May 12, 2014)
- “Expert Discovery, Markman Hearings & Preparing for Trial,” U.S. Patent Litigation Seminar Series, Tokyo, Japan (November 14, 2013)
- “Motions for Summary Judgment, Attorney-Client Privilege and ITC Practice,” U.S. Patent Litigation Seminar Series, Tokyo, Japan (September 12, 2013)
- “Managing E-Discovery in U.S. Patent Litigation,” AIPPI Journal in Japan, Vol. 54, No. 10, 2009
- “Duty of Disclosure Requirements: Best Practice for Handling and Managing Disclosure Requirements,” TACPI D.C. Round Table Seminar (December 18, 2009)
- “Practical Steps to Address E-Discovery: New Battleground in U.S. IP Litigation,” TACPI D.C. Round Table Seminar (August 27, 2009)
- “Strategic Document Management for Corporate IP Practitioners,” presented to NGB and clients in Japan (May 19, 2009)
- “Proper Scope of ITC Remedies After Qualcomm,” IP Law360 (October 22, 2008)
주목해야 할 주요 제약 소송 동향
의료 및 생명과학 산업이 계속 진화함에 따라 전국의 조직은 제약 소송의 최근 동향을 염두에 두어야 합니다. 이 웨비나에서는 독점 금지, 지적 재산권, 대량 불법 행위 소송 또는 기타 소송 문제 등 제약 업계에서 증가하고 있는 제약 트렌드를 자세히 살펴봅니다.
GLP-1 약물 집중 분석: 동향, 요구사항 및 향후 전망
폴리의 헬스케어·생명과학 및 혁신기술 부문에서 주최하는 웨비나에 여러분을 초대합니다. 본 웨비나에서는 귀사가 GLP-1 분야의 교차로에서 방향을 설정하고 진화하는 환경에 대비하는 방법을 논의할 예정입니다.
폴리, 머크의 100억 달러 규모 인수에서 베로나 파마 대표로 활동하다
폴리 앤 라드너 LLP는 영국에 본사를 둔 호흡기 질환 전문 바이오 제약 회사인 베로나 파마가 약 100억 달러에 인수되는 과정에서 미국 지적 재산권 자문사로 활동했습니다. (머크)가 약 100억 달러에 인수하는 과정에서 베로나 파마의 미국 지적재산권 자문을 맡았습니다.
IAM, 2025년판 'IAM 특허 1000: 세계 최고의 특허 실무자'에서 폴리 변호사와 관할 지역을 인정받다
폴리 앤 라드너 LLP의 17명의 변호사와 5개의 로펌이 2025년판 IAM 특허 1000: 세계 최고의 특허 전문가에 선정되었습니다.
GLP-1 수용체 작용제: 약물 소송 개요 및 동향
최근 체중 감량과 비만을 해결하기 위한 GLP-1 약물의 인기가 높아지면서 이 계열의 약물과 관련된 미국 내 소송이 증가하고 있습니다.
2024 폴리 도쿄 IP 컨퍼런스
9월 25일 수요일에 열리는 2024 폴리 도쿄 IP 컨퍼런스 - "혁신의 비즈니스 탐색"에 참여해 주세요: 특허 적격성, AI 및 기타 주요 IP 개발에 대한 인사이트" - 반나절 동안 진행되는 교육 세미나로, 최신 IP 법적 발전과 미국 내 비즈니스에 미치는 실질적인 영향을 안내해 드립니다.